Publications by authors named "Alan Pestronk"

Claim this Profile
A
ACOX1 gain-of-function post-mortem neuropathology is distinct from ACOX1 loss-of-function: case report and literature review.
Zita Hubler, Kaleigh Filisa Roberts, Nima Sharifai, Julia Sim, Sophia A Hung, Alan Pestronk

Free Neuropathol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Density Lipoprotein-Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin-Deficient Limb-Girdle Muscular Dystrophy Type R2.
Zoe White, Laura Rufibach, Heather Gordish Dressman, Heather Hilsden, Dan Cox, Alan Pestronk

J Cachexia Sarcopenia Muscle· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Immune Peripheral Nerve Myelinopathies-A Plea for Precision.
Jesse Crayle, Alan Pestronk

JAMA Neurol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene therapy ameliorates neuromuscular pathology in CLN3 disease.
Ewa A Ziółkowska, Albina Jablonka-Shariff, Letitia L Williams, Matthew J Jansen, Sophie H Wang, Alan Pestronk

Acta Neuropathol Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysferlinopathy as cause of long-term hyperCKemia with preserved strength.
Ikreet Cheema, Jacob Goodwin, Teerin Liewluck, Robert Charles Bucelli, Alan Pestronk

Orphanet J Rare Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Fibroblast Growth Factor Receptor 3 (FGFR3) in the Human Peripheral Nervous System: Implications for the Putative Pathogenic Role of FGFR3 Autoantibodies in Neuropathy.
Alexander Chamessian, Diana Tavares-Ferriera, Maria Payne, Raghav Govindarajan, Alan Pestronk

bioRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seeding-competent TDP-43 persists in human patient and mouse muscle.
Eileen M Lynch, Sara Pittman, Jil Daw, Chiseko Ikenaga, Sheng Chen, Alan Pestronk

Sci Transl Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ophthalmoparesis as an unusual manifestation of anti-3‑hydroxy-3-methyl-glutaryl-coenzyme A reductase antibody-associated myopathies.
Brendan Putko, Alan Pestronk, Gregory P Van Stavern, Cecile L Phan, Grayson Beecher

Neuromuscul Disord· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Rabi Tawil, Kathryn R Wagner, Johanna I Hamel, Doris G Leung, Jeffrey M Statland, Alan Pestronk

Lancet Neurol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seeding competent TDP-43 persists in human patient and mouse muscle.
Eileen M Lynch, Sara Pittman, Jil Daw, Chiseko Ikenaga, Sheng Chen, Alan Pestronk

bioRxiv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biallelic variants in COQ7 cause distal hereditary motor neuropathy with upper motor neuron signs.
Adriana P Rebelo, Pedro J Tomaselli, Jessica Medina, Ying Wang, Maike F Dohrn, Alan Pestronk

Brain· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Schwann cells and myelin in human peripheral nerve: Major protein components vary with age, axon size and pathology.
Alan Pestronk, Robert E Schmidt, Robert Bucelli, Julia Sim

Neuropathol Appl Neurobiol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the muscle imaging spectrum in dysferlinopathy: description of an outlier population from the classical MRI pattern.
Laura Llansó, Ursula Moore, Carla Bolano-Diaz, Meredith James, Andrew M Blamire, Alan Pestronk

Neuromuscul Disord· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy.
Ursula Moore, Esther Fernández-Simón, Marianela Schiava, Dan Cox, Heather Gordish-Dressman, Alan Pestronk

Neuromuscul Disord· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Water T2 could predict functional decline in patients with dysferlinopathy.
Ursula Moore, Ericky Caldas de Almeida Araújo, Harmen Reyngoudt, Heather Gordish-Dressman, Fiona E Smith, Alan Pestronk

J Cachexia Sarcopenia Muscle· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarcoidosis, granulomas and myopathy syndromes: A clinical-pathology review.
Mark Garret, Alan Pestronk

J Neuroimmunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
Jeffrey M Statland, Craig Campbell, Urvi Desai, Chafic Karam, Jordi Díaz-Manera, Alan Pestronk

Muscle Nerve· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease.
Florian P Thomas, Thomas H Brannagan, Russell J Butterfield, Urvi Desai, Ali A Habib, Alan Pestronk

Neurology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal study.
Ursula Moore, Roberto Fernandez-Torron, Marni Jacobs, Heather Gordish-Dressman, Jordi Diaz-Manera, Alan Pestronk

Muscle Nerve· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach.
Anna G Mayhew, Meredith K James, Ursula Moore, Helen Sutherland, Marni Jacobs, Alan Pestronk

Front Neurol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study.
Marie Wencel, Aziz Shaibani, Namita A Goyal, Mazen M Dimachkie, Jaya Trivedi, Alan Pestronk

Neurol Genet· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathology Features of Immune and Inflammatory Myopathies, Including a Polymyositis Pattern, Relate Strongly to Serum Autoantibodies.
Alan Pestronk, Rati Choksi

J Neuropathol Exp Neurol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale.
Marni B Jacobs, Meredoith K James, Linda P Lowes, Lindsay N Alfano, Michelle Eagle, Alan Pestronk

Ann Neurol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease.
Ursula Moore, Heather Gordish, Jordi Diaz-Manera, Meredith K James, Anna G Mayhew, Alan Pestronk

Neuromuscul Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies.
Chiseko Ikenaga, Andrew R Findlay, Namita A Goyal, Sarah Robinson, Jonathan Cauchi, Alan Pestronk

Ann Clin Transl Neurol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis